EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Therapeutic non-compliance with insulin in the treatment of diabetes mellitus 2



Therapeutic non-compliance with insulin in the treatment of diabetes mellitus 2



Atencion Primaria 44(2): 74-81



To determine the percentage of therapeutic noncompliance among type 2 diabetes patients on treatment with insulin. Prospective multicentre study. Nine Primary Care Health Centre in Huelva (Spain). A total of 121 type 2 diabetics, who, in the opinion of their doctor, need to start treatment with insulin or have their insulin treatment modified. Five visits were made (enrolment, 6, 12, 18 and 24 months). The variables analysed were, fasting blood glucose, glycosylated haemoglobin, compliance with insulin treatment, measured by counting insulin units. The percentage compliance (PC) was calculated by (PC = Total No. of insulin units expected to be consumed / Total No. of insulin units that should have been taken x 100). A complier was considered as one who achieved a PC between 80 and 100%. There were 103 evaluable subjects (85.8%) with a mean age of 66.4 (SD 11.6) years, and 45 were male (42.8%). The mean percentage compliance with insulin was 90.9% (95% CI, 84.2-97.6%). At the 6, 12, 18 and 24 months visits it was 92.1% (95% CI, 85.6-98.6%), 92.3, 90.1 and 89.2% (95% CI, 81.7-96.7%), respectively. Overall patient compliance was 74.75% (95% CI, 64.3-85.2%). For the visits, compliance was 82.5% (95% CI, 73.3-91.7%), 77.7%, 73.8% and 71.8% (95% CI, 60.9-82.7%), respectively (P<.05 initial-final). A quarter of the diabetic patients did not comply with their insulin treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 056548513

Download citation: RISBibTeXText

PMID: 22018796

DOI: 10.1016/j.aprim.2010.11.013



Related references

Treatment of insulin dependent diabetes mellitus by multiple insulin injections with a special reference to compliance. Diabetes Research & Clinical Practice (SUPPL 1): S285, 1985

Viruses as therapeutic agents. I. Treatment of nonobese insulin-dependent diabetes mice with virus prevents insulin-dependent diabetes mellitus while maintaining general immune competence. Journal of Experimental Medicine 171(6): 2077-2089, 1990

Validity of 6 indirect methods in the evaluation of compliance to drug treatment of non-insulin dependent diabetes mellitus. Revista Clinica Espanola 197(8): 555-559, 1997

Treatment of diabetes mellitus. 2. Insulin preparations and therapeutic uses. British Medical Journal 1(5134): 1407-1408, 1959

Inhaled insulin--a new therapeutic option in the treatment of diabetes mellitus. Expert Opinion on PharmacoTherapy 4(2): 191-200, 2003

Treatment of diabetes mellitus. I. Insulin: physiological and therapeutic actions. British Medical Journal 1(5132): 1291-1292, 1959

Relationship between medical treatment compliance and the degree of control in patients with high blood pressure, non-insulin dependent diabetes mellitus and dyslipidemia. Medicina Clinica 111(15): 565-567, 1998

Therapeutic effect of human insulin in the treatment of adult-onset diabetes mellitus. Mimura, G, Chi, Z International Congress Series; Recent progress of diabetes mellitus in East Asia: 391-395, 1992

Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering. Annals of the New York Academy of Sciences 1243: E40-E54, 2012

Diethylaminoethyldextran in the treatment of type 2 non insulin dependent diabetes mellitus a new therapeutic frontier. Diabetologia 30(7): 592A, 1987

The relationship between diabetes knowledge and compliance among Chinese with non-insulin dependent diabetes mellitus in Hong Kong. Journal of Advanced Nursing 30(2): 431-438, 1999

Using parlodel as a therapeutic agent in the complex treatment of a patient with insulin dependent diabetes mellitus. Problemy Endokria 30(2): 46-48, 1984

Small molecule activators of the insulin receptor: potential new therapeutic agents for the treatment of diabetes mellitus. Current Medicinal Chemistry 9(24): 2231-2242, 2002

Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. Faseb Journal 24(7): 2583-2590, 2010

The pittsburgh insulin dependent diabetes mellitus study hla antigens and haplotypes as risk factors for the development of insulin dependent diabetes mellitus in insulin dependent diabetes mellitus patients and their siblings. Journal of Chronic Diseases 37(7): 555-568, 1984